Success Story: NIW Approved Without RFE! Medicinal Chemistry Scientist from New Zealand Achieves Seamless Success With Our Expert Guidance

Client’s Testimonial:

“Thank you so much!!!!!! I am so grateful for all your hard work!”

On March 5^th, 2025, we received another EB-2 NIW (National Interest Waiver) approval for a Scientist II, Medicinal Chemistry in the Field of Medicinal Chemistry (Approval Notice).

General Field: Medicinal Chemistry

Position at the Time of Case Filing: Scientist II, Medicinal Chemistry

Country of Origin: New Zealand

State of Residence at the Time of Filing: California

Approval Notice Date: March 5^th, 2025

Processing Time: 15 months, 17 days

Case Summary:

We are pleased to announce the approval of a National Interest Waiver (NIW) petition for a PhD holder whose groundbreaking research focuses on small molecule synthesis and organocatalysis for anticancer drug development. The petition was approved after a thorough review of the client’s academic record, research impact, and demonstrated ability to continue contributing to critical national healthcare needs.

Designing Next-Generation Anticancer Therapies

The petitioner’s proposed endeavor centers on the design and optimization of novel small-molecule therapeutics to improve cancer patient outcomes. Leveraging expertise in synthetic organic chemistry and catalysis, the client develops innovative approaches to construct biologically active compounds. Their work targets difficult-to-treat cancers and addresses urgent medical needs with a strong translational focus.

Currently employed as a medicinal chemist in the biotechnology industry, the petitioner conducts preclinical drug discovery research, synthesizing lead compounds and enhancing their pharmacological profiles. Their work directly supports the development of life-saving oncology drugs, aligning with national priorities in public health and pharmaceutical innovation.

A Proven Track Record of Scientific Impact

At the time of filing, the petitioner had authored 9 peer-reviewed publications, including multiple first-author papers in top-tier journals. Their research has been cited 146 times, and at least two publications rank in the top 10% of most cited articles in their field for their respective publication years. These citations reflect broad recognition and reliance on their work within the scientific community.

In addition, the petitioner has participated in the peer review process for leading academic journals, further establishing their role as a trusted expert in medicinal chemistry.

Endorsements from Esteemed Experts

To further support the case, 2 letters of recommendation from prominent researchers were submitted. These letters attested to the novelty and utility of the petitioner’s methodologies and their contribution to ongoing progress in cancer drug discovery.

“Her specific findings with respect to NHC catalysts and green enantioselective transformation methods, as well as her overall research output, demonstrate that she is an accomplished contributor to the field whose continued presence within the U.S.-based community of researchers is eminently desirable.”

A Strategic and Well-Evidenced Petition

Our legal team highlighted how the petitioner’s education, impactful publication record, and ongoing research position them to continue advancing nationally important work. USCIS agreed, and the petition was approved in just under 16 months without receiving any RFEs.

We are proud to support scientists whose work directly advances public health outcomes and strengthens the nation’s biomedical research leadership.

North America Immigration Law Group (Chen Immigration Law Associates) is a U.S. immigration law firm dedicated to representing corporations, research institutions, and individuals from all 50 U.S. states regarding I-140 immigration petitions. We specialize in employment-based immigration petition and have a proven record of high success rate for the categories of: EB2-NIW (National Interest Waiver), EB1-A (Alien of Extraordinary Ability), EB1-B (Outstanding Researcher/Professor) and O-1 (Alien of Extraordinary Ability).

Our Ten Thousand I-140 Approvals Provide Unprecedented Insight into the USCIS Adjudication Trend

With more than 58,000 EB-1A, EB-1B, EB-2 NIW and O-1 cases approved, we have first hand information on the manner in which the USCIS adjudicate I-140 cases. As the USCIS has constantly changed its adjudication standards for the EB-1A, EB-1B and EB-2 NIW categories, our firm's huge database of successful cases gives you unprecedented insight to USCIS adjudication trends. We carefully analyze the data for all of our cases and apply the results of our analyses toward giving our clients up-to-date advice and adapting our strategies such that we remain on par with the ever-shifting landscape of immigration law in the U.S. With us, you will always have access to important updates, strategies, and information so that you can make the most informed decisions about your case.

We Have Helped Hundreds and Thousands of Clients with Credentials and Backgrounds Similar to Yours

With our exceedingly large number of successful petitions, no matter what credentials you have, no matter your background and field of expertise, no matter your visa status or nationality, chances are we have helped hundreds or even thousands of clients just like you. Our clients are usually impressed with how well we understand their research and work. Our insight and understanding stems from the fact that we have handled many cases with elements similar to yours already, and this helps us devise the best strategies for each individual petition.

Vast Majority of Clients Came to Us Because of Referrals

For years, our firm has attracted new clients based solely on word of mouth, recommendations, and the positive collaboration experiences shared with them by their friends and family. We take pride in our reputation and work hard to ensure that we provide a green card application experience that our clients are happy to share with their friends and colleagues. That is how our cumulative total of approved cases grew from 600 in 2013 to over 58,000 in 2025.